Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

被引:15
作者
Becker, R. H. A. [1 ]
Frick, A. D. [1 ]
Teichert, L. [1 ]
Nosek, L. [2 ]
Heinemann, L. [2 ]
Heise, T. [2 ]
Rave, K. [2 ]
机构
[1] Sanofi Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany
[2] Profil Inst Metab Res, Neuss, Germany
关键词
fluctuation; glucose clamp; insulin glargine; pharmacokinetics; pharmacodynamics; reproducibility;
D O I
10.1111/j.1463-1326.2008.00874.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: Low diurnal fluctuation and high day-to-day reproducibility in exposure and effect characterize beneficial basal insulin products. Two insulin glargine (LANTUS) formulations [without (R) or with polysorbate-20 (T)], added to minimize unfolding of proteins and subsequent formation of fibril structures, were assessed for equivalence in exposure and effect, and aspects of fluctuation and reproducibility in time-concentration and time-action profiles. Methods: A dose of 0.4 U/kg was subcutaneously administered to 24 healthy subjects in a two-sequence (R-T-R-T or T-R-T-R), randomized, four-way crossover trial utilizing 30-h Biostator-based euglycaemic glucose clamps. Results: Identical serum insulin glargine concentration and time-action profiles established average, individual and population equivalence in insulin exposure and effect. Point estimates for 24-h area under the curve for insulin (INS AUC(0-24) (h)) and glucose infusion rates (GIR-AUC(0-24) (h)) were 97% [90% confidence interval (CI): 91-103%] and 100% (88-114%), respectively. Within- subject variability (coefficient of variation) for INS-AUC(0-24) (h) and GIR-AUC(0-24) (h) were 19% ( 95% CI: 14-25%) and 34% (24-43%), respectively. The diurnal relative fluctuation of the serum insulin glargine concentration was 20% (95% CI: 19-21%). Conclusion: Insulin glargine in either formulation presents with a high day-to-day reproducibility of a uniform release after injection enabling an effective basal insulin supplementation.
引用
收藏
页码:1105 / 1113
页数:9
相关论文
共 35 条
[1]  
[Anonymous], 1996, DIABETES, V45, P1289
[2]  
[Anonymous], 2003, GUID IND BIOAV BIOEQ
[3]   Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times [J].
Ashwell, SG ;
Gebbie, J ;
Home, PD .
DIABETIC MEDICINE, 2006, 23 (01) :46-52
[4]  
Benedetti MM, 2003, HORM METAB RES, V35, P189
[5]   Toward understanding insulin fibrillation [J].
Brange, J ;
Andersen, L ;
Laursen, ED ;
Meyn, G ;
Rasmussen, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (05) :517-525
[6]  
Chen ML, 2000, STAT MED, V19, P2821
[7]  
Chinchilli VM, 1996, STAT MED, V15, P1619, DOI 10.1002/(SICI)1097-0258(19960815)15:15<1619::AID-SIM326>3.0.CO
[8]  
2-N
[9]  
Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO
[10]  
2-B